• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 TRANSCATHETER; PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 TRANSCATHETER; PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9600TFX29A
Device Problem Malposition of Device (2616)
Patient Problem Foreign Body Embolism (4439)
Event Date 05/13/2021
Event Type  Injury  
Manufacturer Narrative
Per the instructions for use (ifu), valve embolization is a known potential adverse event associated with the transcatheter pulmonic valve replacement (tpvr) procedure.There are multiple patient and procedural factors that alone or in combination can cause or contribute to pulmonic embolization, including improper positioning prior to deployment, poor image intensifier angle, poor coaxial alignment of the valve and delivery system, severe septal hypertrophy, minimally or bulky/severely calcified pulmonic leaflets, preserved ejection fraction, loss of pacing capture, rapid deployment, release of stored tension during deployment, and movement of the delivery system by the operator.The thv training manuals instruct the operator on proper positioning and deployment of the valve, including all procedural and anatomical considerations.Physicians are extensively trained by edwards before they are qualified to use the sapien 3 thv.Training includes patient screening, device preparation, approach, deployment, imaging, procedure-specific training manuals and proctored procedures.The correct alignment and positioning of the device at the point of deployment is emphasized as a key factor to the placement and fixation of the device.Operators are also instructed to use fluoroscopy as the primary method of visualization for positioning and deployment.In patients with high-risk anatomical features for aortic embolization (i.E.Minimal leaflet calcification, severe septal hypertrophy), bav may provide indication of potential balloon movement during valve deployment.In this case, there was no allegation or indication a device malfunction contributed to this adverse event.Investigation results suggest possible interaction between the delivery system balloon and the deployed valve during withdrawal of the delivery system may have contributed to the initial movement of the deployed valve.The attempts to recapture and reposition the valve likely contributed to the embolization into the rvot and subsequent explant and surgical repair of the pulmonic valve.The ifu and training manuals have been reviewed and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review.No corrective or preventative actions are required.
 
Event Description
During a transcatheter pulmonary valve replacement (tpvr) procedure, post deployment, the sapien 3 valve embolized.As reported, a 29mm sapien 3 valve was prepared with nominal plus 3cc of inflation fluid.The valve was deployed in a pre-existing transannular patch in the pulmonic position.The valve landed 'perfectly' at the waist, which measured 25mm to 26mm.No paravalvular leak (pvl) was observed.Upon attempting to retrieve the delivery system inflation balloon from the valve, the valve 'slipped down'.During the attempt to capture and reposition the valve, the valve slipped down into the rvot.The patient was transferred to surgery.The valve was explanted, and the pulmonic valve was surgically repaired.At the time of the report, the patient was in stable condition.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS SAPIEN 3 TRANSCATHETER
Type of Device
PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
renee van dorne
1 edwards way
irvine, CA 92614
9492506385
MDR Report Key11925879
MDR Text Key254075843
Report Number2015691-2021-03278
Device Sequence Number1
Product Code NPV
UDI-Device Identifier00690103194364
UDI-Public(01)00690103194364(17)220909
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P200015
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial
Report Date 06/02/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date09/09/2022
Device Model Number9600TFX29A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 05/13/2021
Initial Date FDA Received06/02/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/29/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age10 YR
-
-